{"id":"W3178692749","doi":"10.1016/j.euo.2021.05.007","title":"Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial","year":2021,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Axitinib; Pembrolizumab; Discontinuation; Sunitinib; Adverse effect; Internal medicine; Renal cell carcinoma; Gastroenterology; Incidence (geometry); Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001733447,0.0005336305,0.001276606,0.0002114962,0.0002175604,0.001036506,0.0004116987,0.0004600405,0.001324967],"category_scores_gemma":[0.001656994,0.0002007728,0.001391497,0.0004656618,0.0003789776,0.0007340851,0.0003245512,0.001720962,0.0002141308],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009873261,"about_ca_system_score_gemma":0.0007682431,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008380193,"about_ca_topic_score_gemma":0.003276782,"domain_scores_codex":[0.9993691,0.0003467112,0.0000359398,0.00009054172,0.00006606218,0.00009160454],"domain_scores_gemma":[0.9993438,0.0001907622,0.0002085027,0.00006179772,0.0000453061,0.0001499087],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6050307,0.007726849,0.07790118,0.002370076,0.009241236,0.0002891206,0.0003066384,0.005503471,0.01332123,0.0006545126,0.007946094,0.2697088],"study_design_scores_gemma":[0.3746477,0.1901067,0.3906799,0.0004828422,0.01057553,0.001762439,0.0004380899,0.005995205,0.00565749,0.002624287,0.01686699,0.0001627592],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9906576,0.005435286,0.0001957193,0.0004035009,0.0000716793,0.0002224691,0.0009066822,0.00002896089,0.002078104],"genre_scores_gemma":[0.9940873,0.001547124,0.0003602251,0.0006339212,0.00009409845,0.0001552186,0.002409881,0.00001072631,0.0007013784],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001733447,"threshold_uncertainty_score":0.009167492,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02050670095494227,"score_gpt":0.2432564093743557,"score_spread":0.2227497084194134,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}